Arena Pharmaceuticals, Inc.

Phase II study initiated for anti-obesity compound

Published in Fitness and Wellness Business Week, February 9th, 2005

Arena Pharmaceuticals, Inc., (ARNA) announced that it has started dosing patients in a phase II clinical trial of APD356, an orally administered small molecule designed to regulate satiety for the treatment of obesity.

This compound is a selective agonist of 5-HT2C serotonin receptors, which are concentrated in the hypothalamus, an area of the brain known to play an important role in regulating food intake and metabolism.

This phase II clinical trial of APD356 is a randomized, double-blinded, multiple-dose, 28-day trial examining 400 obese volunteers. Arena expects that the trial will compare doses of 1, 5 and 15 mg of APD356 to a placebo and will...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Fitness and Wellness Business Week

Source: Fitness and Wellness Business Week (2005-02-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry